Assessing the effect of foreign travel and protection by BCG vaccination on the spread of tuberculosis in a low incidence country, United Kingdom, October 2008 to December 2009. by Abubakar, I et al.
Abubakar, I; Matthews, T; Harmer, D; Okereke, E; Crawford, K;
Hall, T; Collyns, T; Smith, G; Barrett, A; Baugh, S (2011) Assessing
the effect of foreign travel and protection by BCG vaccination on the
spread of tuberculosis in a low incidence country, United Kingdom,
October 2008 to December 2009. Euro surveillance, 16 (12). ISSN
1025-496X
Downloaded from: http://researchonline.lshtm.ac.uk/502/
DOI:
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
1www.eurosurveillance.org
Research articles
Assessing the effect of foreign travel and protection by 
BCG vaccination on the spread of tuberculosis in a low 
incidence country, United Kingdom, October 2008 to 
December 2009
I Abubakar (ibrahim.abubakar@hpa.org.uk)1,2, T Matthews2,3, D Harmer3, E Okereke4, K Crawford3, T Hall3, T Collyns5, G Smith6,
A Barrett7, S Baugh8
1. Tuberculosis Section, Health Protection Agency Centre for Infections, Colindale, London, United Kingdom
2. These authors contributed equally to the manuscript
3. North Yorkshire and Humber Health Protection Unit, Hull, United Kingdom
4. Health Protection Agency Yorkshire and Humber, Leeds, United Kingdom
5. Leeds Teaching Hospitals Trust, St James’ University Hospital, Leeds, United Kingdom 
6. Health Protection Agency Regional Centre for Mycobacteriology, Birmingham, United Kingdom
7. Health Protection Agency Regional Centre for Mycobacteriology, Newcastle, United Kingdom
8. Northern Lincolnshire and Goole Hospitals National Health Service Foundation Trust, United Kingdom
Citation style for this article: 
Abubakar I, Matthews T, Harmer D, Okereke E, Crawford K, Hall T, Collyns T, Smith G, Barrett A, Baugh S. Assessing the effect of foreign travel and protection by 
BCG vaccination on the spread of tuberculosis in a low incidence country, United Kingdom, October 2008 to December 2009 . Euro Surveill. 2011;16(12):pii=19826. 
Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19826 
Article published on 24 March 2011
The contribution of travel to high incidence countries 
and the impact of the discontinuation of universal 
Bacillus Calmette–Guérin (BCG) vaccination to the 
recent rise in tuberculosis (TB) in the United Kingdom 
remain unclear. An outbreak in a college presented 
an opportunity to assess these. A cohort of students 
answered a questionnaire assessing risk factors for TB. 
Participants were screened with an interferon gamma 
release assay (IGRA). Unadjusted and adjusted odds 
ratios (OR) were calculated using logistic regression. 
Among 2,284 students, 400 (17.5%) were diagnosed 
with TB infection. A higher risk was noted for travel to 
a high incidence area in the past two years (OR: 1.39; 
95% confidence interval (CI): 1.04–1.89) and among 
those with the greatest exposure to the index case 
(OR: 3.94; 95% CI: 2.60–5.97). There was no associa-
tion between BCG and risk of infection (OR: 1.05; 95% 
CI: 0.80–1.39). The lack of a protective effect by BCG 
on TB infection supports the discontinuation of uni-
versal vaccination. The association with foreign travel 
suggests the need to assess the cost-effectiveness of 
serial IGRA testing and treatment of positive persons 
among returning travellers.
Introduction
Countries with a low tuberculosis (TB) incidence, espe-
cially those heading towards elimination of the disease, 
have a policy of identifying individuals with presumed 
latent TB infection and offering prophylactic treatment 
[1,2]. In general, the policy prioritises the screening of 
recently exposed persons due to a higher risk of pro-
gression to active TB, often using a ‘stone in the pond’ 
approach [3]. This, together with the prompt diagnosis 
and adequate treatment of active cases, forms the cor-
nerstone of TB control policy in countries with a low TB 
incidence.
The major burden of TB in many low-incidence high-
income countries is in immigrants, their descendants 
and in particular high-risk groups such as the home-
less, drug users and prisoners [4-6]. By contrast, for 
the rest of the population in these countries, the risk 
of TB remains low outside of outbreaks. The higher risk 
among the foreign-born is thought to be a function of 
infection prior to immigration and, to a lesser extent, 
travel to high TB incidence countries and transmission 
within immigrant communities. It is not clear however, 
to what extent each of these factors increases the risk 
of TB. 
The Bacillus Calmette–Guérin (BCG) vaccine is the only 
preventive immunisation currently available against 
TB. Evidence suggests that it is effective in preventing 
meningitis and miliary TB in young children [7,8]. In the 
United Kingdom (UK), there is also evidence that BCG 
protects against pulmonary TB among school-aged 
children [9,10]. Most countries, including those with 
low TB incidence, have a BCG vaccination policy that 
may be universal or targeted. For low-incidence coun-
tries, a policy switch from universal to targeted BCG 
vaccination was supported by criteria put forward by 
the International Union Against Tuberculosis and Lung 
Disease in the 1990s [11]. Several countries with a low 
TB incidence, including the UK [12], have now changed 
their BCG vaccination policy to target high-risk groups. 
To date, the effect of this policy change has not been 
evaluated in the UK. In the United States (US), the 
poor efficacy of BCG following initial trials and its con-
founding effect on tuberculin skin testing led to the 
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exclusion of BCG from the immunisation schedule [13]. 
The US guidelines allow the use of BCG in specific cir-
cumstances such as in children who cannot be removed 
from the source case. Arguably, if BCG is found to be 
efficacious against latent infection [14], and a person 
is travelling to a country with a high TB incidence and 
significant levels of anti-TB drug resistance, it may be 
justifiable to use the same rationale to offer BCG.
Following the diagnosis of sputum smear-positive 
cavitatory pulmonary TB in a college student, the 
local Health Protection Unit, working closely with the 
Respiratory Medicine Service and Primary Care Trust, 
screened 2,284 students and 299 staff members with 
an interferon gamma release assay (IGRA) and, where 
appropriate, chest X-ray examination. The students at 
the college were evenly divided in two groups: the age 
group vaccinated as part of the universal school-age 
BCG vaccination policy in the UK, and the group who 
reached the relevant age after the policy was changed. 
The investigation identified 19 cases of active TB. This 
outbreak presented an opportunity to assess the rela-
tive contribution of foreign birth, recent travel to a high 
incidence setting, community transmission (based on 
contact with a TB case and non-white ethnicity) and the 
protective effect of BCG vaccination. 
We formed the hypotheses that, in addition to place of 
birth and exposure to the index case, travel to a high 
incidence country and BCG vaccination may predict 
latent infection as measured by a positive IGRA. The 
BCG policy change and a well-defined cohort exposed 
to a known infectious case allowed us to test these 
hypotheses.
Methods 
Participants
The study population consisted of all students attend-
ing the college during daytime. All participants were 
aged over 16 years. Staff who directly taught these 
students were also screened. Between October 2008 
and December 2009, students, friends of the index 
case and staff at the college were interviewed. It took 
a long time to complete the examination of all contacts 
because we used the ‘stone in the pond’ approach, 
where a small proportion of contacts were screened 
and further circles for testing were identified if the 
level of infection found was higher than expected, until 
eventually all exposed students were screened. 
Ascertainment of risk factors
Interviews were used to collect information from all 
2,284 students about: 
•	 place of birth, and if born abroad, year of entry in 
the UK, 
•	 previous contact with TB in the household, 
•	 age, 
•	 sex, 
•	 ethnic group, broadly classified as Asian, White, 
Black, mixed or other, 
•	 history of travel to a country outside western 
Europe, North America and Australasia in the pre-
ceding two years, 
•	 history of BCG vaccination ascertained through 
the inspection of a scar or reliable recollection of 
vaccination, 
•	 symptoms suggestive of TB. 
The incidence of TB in the local area in 2007 was 4 
per 100,000 with most cases occurring in non-White 
ethnic groups (T. Matthews, personal communication, 
Jan 2009). Based on this, we used non-White ethnic-
ity as a marker of community risk of TB. At the same 
time a blood sample was drawn from each participant 
for IGRA testing. IGRA tests have been shown to have 
at least an equivalent level of diagnostic accuracy for 
latent TB infection compared with the tuberculin skin 
test (TST) [15]. Emerging evidence suggests that the 
predictive value of IGRAs for the development of active 
TB is also higher than [16] or equivalent to TST [17,18].
Clinical and laboratory investigation
Contacts were investigated in concentric circles of 
decreasing exposure in three groups based on expo-
sure times over the 17 days that the index case was 
at the college while infectious. Group 1 was screened 
between November 2008 and January 2009 and 
included students who shared classrooms with the 
index case with cumulative exposures of more than 
two hours, or friends of the index case. Group 2 was 
screened in February 2009 and included students who 
attended the same general study class as the index 
case, with cumulative exposure time between one and 
two hours in a large hall setting. Group 3 was screened 
between July and August 2009 and included the rest of 
the college. Following the first two circles of screening, 
270 students whose initial IGRA test had been negative 
or indeterminate were tested again. 
Two IGRA tests were used, Quantiferon-TB Gold in tube 
test (QGIT, Cellestis) and T-Spot TB (Oxford Immunotec). 
For the majority of participants, the QGIT test was 
used. A small proportion of individuals were tested 
with T-Spot TB, and those with a negative result were 
retested using QGIT during the third circle of screen-
ing. Both IGRA tests use the region of difference-1 
antigens early secretory antigen target 6 (ESAT-6) and 
culture filtrate protein 10 (CFP 10), and in addition QGIT 
includes TB7.7, to stimulate T-effector cells specific 
for Mycobacterium tuberculosis to produce gamma-
interferon. Those with a positive IGRA result from any 
screening round were recalled for a chest X-ray exami-
nation and clinical review at a respiratory medicine 
clinic. Preventive therapy was offered to individuals 
younger than 35 years with a positive IGRA result but 
no evidence of active TB, according to national guide-
lines [1]. No formal ethical review was required as this 
was done as part of a service response.
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Definitions
Participants were considered to have TB infection if 
they had a positive IGRA test or had active disease.
Statistical methods
Data were entered into a specifically designed database 
in Microsoft Access. Proportions were calculated for 
categorical variables and medians with inter-quartile 
ranges for continuous variables. We used univariable 
and multivariable logistic regression to investigate fac-
tors associated with a positive IGRA result as a proxy 
for latent infection. All variables considered a priori to 
be risk factors for TB were included in the model. We 
investigated the interaction between risk factors for 
TB using the likelihood ratio test. Data were analysed 
using the statistical software Stata 11.
Results
The median age of students was 17.8 years (interquar-
tile range (IQR): 17.3–18.5 years) and 1,055 (46.2%) 
were male (Table 1). Characteristics of the students 
are summarised in Table 1. Among the students, 49.6% 
were BCG-vaccinated, 90.2% were of white ethnicity, 
and 18.8% had travelled within the last two years to 
a high incidence country, including Bangladesh, China, 
India, Russia, and several countries in Sub-Saharan 
Africa. 
Table 1
Characteristics of the student population, tuberculosis 
college outbreak, United Kingdom, October 2008–
December 2009 (n=2,284)
Characteristica Category n (%)
Demographic
Age, median (IQR) 17.8 (17.3–18.5)
Sex
Male 1,055 (46.2)
Female 1,229 (53.8)
Exposure 
Group 1b 131 (5.7)
Group 2 244 (10.7)
Group 3 1,909 (83.6)
Household history
Yes 82 (3.6)
No 2,162 (96.4)
Place of birth
UK 2,089 (91.6)
Not UK 192 (8.4)
Travel in the last two yearsc
Yes 422 (19)
No 1,799 (81)
Ethnicity
White 2,061 (90.2)
Asian 170 (7.4)
Black 10 (0.4)
Mixed 29 (1.27)
Other 14 (0.6)
Clinical
BCG-vaccinated
Yes 1,067 (49.6)
No 1,082 (50.4)
IGRA 
Positive 400 (17.5)
Negative 1,884 (82.5)
Chemoprophylaxis
Yes 349 (15.7)
No 1,912 (84.3)
BCG: Bacillus Calmette–Guérin; IGRA: interferon gamma release 
assay; IQR: inter-quartile range; UK: United Kingdom. 
a For participants for whom information on the respective variable 
was available. 
b This number is different from the Figure 2 as it only includes 
students (not friends).
c Countries travelled to include Bangladesh, China, India, Russia 
and several countries in Sub-Saharan Africa.
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Figure 1
Active tuberculosis cases, college outbreak, United 
Kingdom, October 2008–December 2009 (n=20) 
Group 1: cumulative exposure ≥ 2h in classroom groups to the 
index case and friends of the index case. Numbers here differ from 
those in the Tables, where only students are taken into account . 
Group 2: students exposed 1–2h in a large hall setting. 
Group 3: rest of the college. Other: screened in Groups 2 and 3 but 
diagnosed subsequently by their family doctor or local hospital.
Figure 2
Proportion of students with latent tuberculosis infection 
and active tuberculosis by screening circles, college 
outbreak, United Kingdom, October 2008–December 2009 
(n=2,284)
IGRA: interferon gamma release assay; TB: tuberculosis.
Group 1: cumulative exposure ≥ 2h in classroom groups to the 
index case and friends of the index case. Nine of the 22 friends 
were also students. Numbers here differ from those in the tables, 
where only students are taken into account. 
Group 2: students exposed 1–2h in a large hall setting. 
Group 3: rest of the college.
Group 3
Active TB: 10 cases
IGRA-postive: 306/1,906
Group 2
Active TB: 5 cases
IGRA-positive: 38/240 
Group 1
Active TB
Students: 4 cases, 
of whom friends: 3 cases 
IGRA-positive
Students: 61/129
Friends: 18/22
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The characteristics of the 19 active TB cases are 
described in detail elsewhere [19]. In brief, Figure 1 
shows the distribution of cases over time with seven 
of the eight cases  confirmed by bacterial culture shar-
ing an identical 24 loci MIRU VNTR pattern (42234 
2742511334 422423255) with the index case. 
The median age of all the staff was 46.8 years (IQR: 
38.5 to 55.3 years), and 114 (38.1%) were male. Of 299 
staff members, 48 (16.1%) had a positive IGRA test. No 
active TB cases were diagnosed among staff members.
Characteristics of and factors associated 
with TB infection among students
Of the 2,284 students screened, 400 (17.5%) had evi-
dence of TB infection. A further five friends had a posi-
tive IGRA test (shown in Figure 2) but were not included 
in this analysis as they were not students at the col-
lege. Figure 2 shows the number of individuals with a 
positive IGRA result including those with active TB in 
each circle of screening. The proportion of participants 
positive in the first, second and third circle of screen-
ing were 49.6%, 15.8% and 16.0% respectively. In 
addition, 11 of 270 students converted from an initial 
negative to a positive IGRA result in the third round 
of screening. The index case had 22 friends who were 
identified as close contacts, 16 of whom also attended 
the same college. Thirteen of those 16 were positive. 
Five of the six non-college friends had a positive IGRA 
result. All 400 students were offered preventive treat-
ment according to national guidelines.
In the univariable analysis, being male and/or having 
a history of travel to a high-incidence country in the 
last two years were both positively associated with 
an increased risk of a positive IGRA result (Table 2). A 
sub-analysis conducted with only UK-born individuals 
did not change the outcome (data not shown). Being of 
white ethnicity and/or being in exposure Groups 2 or 
3 were both associated with a lower risk of a positive 
IGRA result. In the fully adjusted model, being male 
(odds ratio (OR): 1.28; 95% confidence interval (CI): 
1.02–1.62; p=0.035), being more exposed (exposure 
Group 1 compared to Group 3) (OR: 3.94; 95% CI: 2.60–
5.97), and having a history of travel to a high incidence 
country in the last two years (OR: 1.39; 95% CI: 1.04–
1.89; p=0.028) remained associated with an increased 
risk of being infected at statistically significant level 
(Table 2). There was no evidence of a protective effect 
of BCG vaccination on TB infection (OR: 1.05; 95% CI: 
0.80–1.39) and no statistically significant evidence of 
interaction between any of the risk factors.
Discussion
This study found a significant association between 
travel to high-incidence countries and the risk of latent 
TB infection among students. As expected, students in 
close contact with the index case were more likely to 
have evidence of latent infection. BCG vaccination did 
not have an effect on TB infection among the student 
population. 
The level of latent infection found is higher than would 
be expected in a low incidence area. Although the inci-
dence of TB has increased in the UK over the last two 
Table 2
Risk factors for tuberculosis infectiona among students, college outbreak, United Kingdom, October 2008–December 2009 
(n=2,284)
Characteristic n (%) UnivariableOR (95% CI)
Multivariable
OR (95% CI) p value
b
Age, median (IQR) 17 (17-18) 1.01 (0.88-1.17) 1.04 (0.87-1.24) 0.694
Sex 
Female 192 (15.8) 1 1
Male 209 (19.9) 1.32 (1.06-1.64) 1.28 (1.02-1.62) 0.035
Exposure
Group 1 58 (47.1) 4.84 (3.35-6.98) 3.94 (2.60-5.97)
Group 2 38 (15.8) 0 (0.13-0.36) 0.84 (0.55-1.29)
Group 3 306 (16.5) 1 1 0.001
Household history
No 379 (17.6) 1 1
Yes 16 (19.5) 1.13 (0.65-1.98) 1.41 (0.79-2.53) 0.247
Place of birth
Not UK 41 (21.3) 1 1
UK 357 (17.2) 0.77 (0.53-1.10) 1.05 (0.61-1.81) 0.852
Travel in last 2 years
No 299 (16.7) 1 1
Yes 91 (21.6) 1.38 (1.06-1.79) 1.39 (1.04-1.89) 0.028
Ethnicity
Non-White 51 (22.9) 1 1
White 349 (17.1) 0.69 (0.50-0.97) 0.84 (0.51-1.37) 0.491
BCG-vaccinated
No 185 (17.2) 1 1
Yes 186 (17.5) 1.02 (0.81-1.28) 1.05 (0.80-1.39) 0.723
BCG: Bacillus Calmette-Guérin; CI: confidence Interval; IQR: interquartile range; OR: odds ratio; UK: United Kingdom.
a Tuberculosis infection includes all students with a positive IGRA and all students with active tuberculosis. The numbers therefore differ 
from the Table 1 which includes only IGRA positives. 
b p values derived using likelihood ratio tests.
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decades [20], the rate of active TB identified in this col-
lege is several times higher than the rate for England 
in the equivalent age group. Indeed, in the preceding 
six years in the local Health Protection Unit area, only 
10 people aged 16 to 20 years were diagnosed with 
TB. The proportion of students with latent infection in 
this college was similar to that observed in previously 
reported school outbreaks in the UK [21,22]. These 
other outbreaks occurred in schools with a high eth-
nic minority population where the high proportion with 
latent infection could, at least in part, be explained by 
a high background rate. This is unlikely in the setting 
described here as the proportion of ethnic minorities in 
the local population was very low. The low proportion of 
non-White ethnicity may also explain the lack of asso-
ciation with TB in the regression model. It is possible 
that in addition to the index case, other pulmonary TB 
cases within the school, possibly the smear-negative 
culture-positive cases, contributed to the transmission 
[23]. Figure 1 suggests this explanation is possible but 
does not prove it. An alternative explanation is that 
the index case was particularly infectious. Eighteen of 
22 friends of the index case were infected, suggesting 
high infectiousness. 
The significant association observed with travel to 
countries with a high incidence of TB, independent of 
exposure to the index case, provides an alternative 
explanation for the higher than expected rate of latent 
infection observed in the school. Previous studies have 
linked travel to high incidence countries with a higher 
risk of infection [24,25]. Based on these studies, 
Cobelens et al. [25] recommend that people travelling 
from low incidence countries to areas highly endemic 
for TB should be offered serial testing or BCG vacci-
nation. To detect an effect, Cobelens et al. followed a 
cohort travelling to countries with very high TB ende-
micity with an annual risk of infection above 1% and 
found an increased risk associated with travel to high 
TB endemic countries. A previous descriptive UK study 
suggested a higher risk of active TB among individuals 
from the Indian sub-continent following return visits 
[26], although subsequent comparison with a control 
group found no association [27]. The study presented 
here provides the first evidence in the UK that travel 
to countries with high levels of TB infection may be an 
independent risk factor for acquiring latent TB infec-
tion. This effect was not mitigated by BCG vaccination. 
Unlike previous studies, we utilised IGRA tests not 
confounded by the majority of non-tuberculous myco-
bacteria or BCG vaccination. The observed increased 
risk is therefore likely to be a result of true latent TB 
infection acquired either during or prior to the current 
incident. 
Acquisition of TB during foreign travel is particularly 
important because the incidence of multi- and exten-
sively drug-resistant TB is higher in many parts of 
the world compared to the UK [28,29]. These strains 
may be acquired while travelling, with the potential 
for subsequent spread upon return to a low incidence 
country. An approach to reduce the incidence of travel-
acquired TB is to use serial TST before and after travel 
and treat those converting to a positive test for latent 
infection [25]. Unfortunately the acquisition of resist-
ant strains would make this approach less effective, 
with limited options for the treatment of latent infec-
tion due to multi- and extensively drug-resistant TB 
[30]. Furthermore, some individuals will convert from a 
negative to a positive TST due to previous exposure to 
non-tuberculous mycobacteria.
That we did not observe protection by BCG against 
latent infection may reflect a true lack of effect against 
latent infection. It is widely accepted that BCG only 
protects against severe forms of TB in infants [31], 
however, emerging evidence suggests that it may also 
protect against latent infection [32,14]. As a result, 
alternative explanations for the absence of a protec-
tive BCG effect against latent infection among students 
have to be considered. As BCG immunisation policy 
in the UK includes the selective vaccination of infants 
at high risk, it is possible that vaccinated individuals 
were more likely to have been exposed to TB, leading 
to a failure to detect a protective effect. Analysis of our 
data, however, suggests that this is unlikely, as the 
observation was independent of the age at BCG vac-
cination. In addition, controlling for ethnic origin, the 
main criterion for selecting who to vaccinate, did not 
change the findings. Significant variation in the effi-
cacy of BCG has been observed in different countries 
[8]. The reasons for variation, including exposure to 
non-tuberculous mycobacteria, latitude, use of differ-
ent strains of the vaccine and genetic differences of the 
vaccinees have been discussed extensively [33] but do 
not provide an obvious explanation for the observed 
lack of effect in this study.
The retrospective collection of data on risk factors in 
our investigation limits the ability to infer a causal link 
with exposures such as travel history and BCG vaccina-
tion status due to the possibility of recall bias. For the 
majority of participants, we obtained TB exposure his-
tory and risk factor data at the time of initial screening, 
before the IGRA test results were known, and thereby 
minimised recall bias. Any bias would therefore have 
been non-differential reducing the probability of 
detecting a true effect. We did not collect baseline 
IGRA data, therefore some of the IGRA-positive per-
sons may have acquired their latent infection remotely. 
Nevertheless, the high proportion of students with 
latent infection in a low-incidence area, the proportion 
of students who converted and the high proportion of 
cases of active TB with the same genotype suggest 
that we were observing the effects of recent transmis-
sion. As we identified, interviewed and tested the vast 
majority of the target population, our findings are not 
affected by non-response bias. Travel history, on the 
other hand, may have been biased because the expo-
sure recorded over the preceding two years may merely 
reflect longer-term travel. However, this is unlikely 
to invalidate the observed association with travel. A 
6 www.eurosurveillance.org
further source of bias relates to the lack of vaccination 
cards to confirm the history of BCG vaccination. This is 
particularly important for children born abroad or from 
ethnic minority groups where scars may be less reli-
able due to vaccination at birth. Finally, although we 
used multivariable regression to adjust for the effect 
of several factors, residual confounding cannot be 
excluded.
The long time it took to screen the entire school pos-
sibly contributed to the emergence of secondary cases. 
While this may in part question the ‘stone in the pond’ 
approach, we contend that this incident is unusual. It 
is likely that controlling for exposure group accounted 
for the effect of secondary transmission in the analysis 
with infection as the outcome measure. 
This study has found a significant association between 
travel to countries with a high TB incidence and the risk 
of latent TB infection among college students. The lack 
of a protective effect by BCG shows that an increased 
risk for TB infection during outbreaks may not be miti-
gated by a universal vaccination approach. This pro-
vides support for the discontinuation of universal BCG 
vaccination of children at school age. Travel appears to 
be an independent risk factor for the acquisition of TB 
infection. In the UK, BCG vaccination is currently rec-
ommended to people travelling to high-incidence coun-
tries for longer than three months. A cost-effectiveness 
analysis of the screening of travellers suggested that 
a single post-travel tuberculin skin test is the best 
approach [34]. However, this study did not assess the 
use of IGRAs. As IGRAs are not confounded by non-
tuberculous mycobacterial infection, future studies 
should evaluate the effectiveness and cost-effective-
ness of a policy requiring serial IGRA testing of travel-
lers and treatment of IGRA-positive persons upon their 
return from high-incidence countries.
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